Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$8.63 - $15.52 $251,788 - $452,811
29,176 Added 10.75%
300,621 $2.66 Million
Q2 2022

Aug 12, 2022

SELL
$8.59 - $20.77 $81,381 - $196,774
-9,474 Reduced 3.37%
271,445 $3.43 Million
Q1 2022

May 16, 2022

SELL
$15.52 - $35.65 $404,125 - $928,290
-26,039 Reduced 8.48%
280,919 $5.31 Million
Q4 2021

Feb 14, 2022

SELL
$28.89 - $35.33 $3.35 Million - $4.09 Million
-115,806 Reduced 27.39%
306,958 $10.8 Million
Q3 2021

Nov 15, 2021

BUY
$35.66 - $42.94 $799,104 - $962,242
22,409 Added 5.6%
422,764 $15.5 Million
Q2 2021

Aug 16, 2021

BUY
$23.7 - $39.27 $695,215 - $1.15 Million
29,334 Added 7.91%
400,355 $15.7 Million
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $22,202 - $30,249
822 Added 0.22%
371,021 $10.5 Million
Q4 2020

Mar 01, 2021

BUY
$27.51 - $34.36 $1.72 Million - $2.15 Million
62,704 Added 20.39%
370,199 $11.9 Million
Q3 2020

Nov 13, 2020

BUY
$25.8 - $34.61 $1.72 Million - $2.3 Million
66,476 Added 27.58%
307,495 $9.93 Million
Q2 2020

Aug 14, 2020

SELL
$17.65 - $28.05 $108,812 - $172,928
-6,165 Reduced 2.49%
241,019 $6.65 Million
Q1 2020

May 15, 2020

BUY
$15.19 - $29.51 $120,001 - $233,129
7,900 Added 3.3%
247,184 $4.41 Million
Q4 2019

Feb 14, 2020

BUY
$17.17 - $25.95 $177,537 - $268,323
10,340 Added 4.52%
239,284 $6 Million
Q3 2019

Nov 14, 2019

BUY
$17.84 - $22.69 $699,113 - $889,175
39,188 Added 20.65%
228,944 $4.08 Million
Q2 2019

Aug 15, 2019

BUY
$22.0 - $31.78 $369,600 - $533,904
16,800 Added 9.71%
189,756 $0
Q1 2019

May 14, 2019

BUY
$21.27 - $30.58 $408,384 - $587,136
19,200 Added 12.49%
172,956 $0
Q4 2018

Feb 13, 2019

BUY
$23.09 - $37.69 $3.55 Million - $5.8 Million
153,756 New
153,756 $3.55 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.